It's Official! Curing Patients Is Bad for Business

[McFurd]

Medpage Today - 4/18/2018 - Milton Packer MD - Pharmaceutical companies are developing new drugs in only two therapeutic areas these days -- cancer and rare diseases. Why? These are the only therapeutic areas where exorbitant pricing is tolerated by payers. How exorbitant are we talking about? Most new drugs for cancer and rare diseases are being priced above $400,000 a year per patient. Some drugs are being priced at $1 million per treatment. And prices continue to soar. Read more @ https://www.medpagetoday.com/blogs/revo ... tion/72407